Publicação
Harnessing complex metabolic signatures to predict drug efficacy in ovarian cancer
| Resumo: | "Ovarian carcinoma (OvC) is the most lethal gynecologic malignancy. Unfortunately, most cases are diagnosed at the later stages of the disease, impacting patient outcomes, resulting in a 5-year survival rate of less than 40%. The standard-of-care (SOC) treatment consists of cytoreduction surgery for tumor debulking and adjuvant chemotherapy, comprising a combination of platinum (cisplatin or carboplatin) with taxane (paclitaxel or docetaxel) agents.(...)" |
|---|---|
| Autores principais: | Mendes, Ana Rita Soares |
| Assunto: | precision medicine ovarian cancer |
| Ano: | 2022 |
| País: | Portugal |
| Tipo de documento: | tese de doutoramento |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| Resumo: | "Ovarian carcinoma (OvC) is the most lethal gynecologic malignancy. Unfortunately, most cases are diagnosed at the later stages of the disease, impacting patient outcomes, resulting in a 5-year survival rate of less than 40%. The standard-of-care (SOC) treatment consists of cytoreduction surgery for tumor debulking and adjuvant chemotherapy, comprising a combination of platinum (cisplatin or carboplatin) with taxane (paclitaxel or docetaxel) agents.(...)" |
|---|